Utility of Bromelain and N-Acetylcysteine in Treatment of Peritoneal Dissemination of Gastrointestinal Mucin-Producing M
This volume will describe both growth-inhibitory and mucin-depleting effects of bromelain and N-acetylcysteine, on their own or in combination, in cancer. It will coherently review the pathophysiological aspects of the mucin glycoproteins in malignancies
- PDF / 2,245,175 Bytes
- 246 Pages / 439.42 x 683.15 pts Page_size
- 29 Downloads / 173 Views
lity of Bromelain and N-Acetylcysteine in Treatment of Peritoneal Dissemination of Gastrointestinal MucinProducing Malignancies
Utility of Bromelain and N-Acetylcysteine in Treatment of Peritoneal Dissemination of Gastrointestinal Mucin-Producing Malignancies
Afshin Amini • Samar Masoumi-Moghaddam David L. Morris
Utility of Bromelain and N-Acetylcysteine in Treatment of Peritoneal Dissemination of Gastrointestinal Mucin-Producing Malignancies
Afshin Amini St. George Hospital The University of New South Wales Kogarah, NSW, Australia
Samar Masoumi-Moghaddam St. George Hospital The University of New South Wales Kogarah, NSW, Australia
David L. Morris St. George Hospital The University of New South Wales Kogarah, NSW, Australia
ISBN 978-3-319-28568-9 ISBN 978-3-319-28570-2 DOI 10.1007/978-3-319-28570-2
(eBook)
Library of Congress Control Number: 2016931439 Springer Cham Heidelberg New York Dordrecht London © Springer International Publishing Switzerland 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Springer International Publishing AG Switzerland is part of Springer Science+Business Media (www.springer.com)
Preface
Gastrointestinal cancers account for more than one third of all deaths from cancer. Peritoneal dissemination is considered as an advanced stage in the natural history of these malignancies and a frequent finding in the recurrent condition. As a curative approach to peritoneal surface malignancies confined to the peritoneal cavity, cytoreductive surgery combined with perioperative intraperitoneal chemotherapy has brought about long-term benefits in selected patients with peritoneal carcinomatosis (PC) of gastrointestinal origin and pseudomyxoma peritonei (PMP) syndrome. However, intraperitoneal chemotherapy fails to maintain the surgical complete response in a proportion of patients with gastrointestinal PC and PMP. In this context, mucins aberrantly expressed by tumor cells are believed to play key roles in tumor biology
Data Loading...
